EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Boehringer Ingelheim partnered with Inflammasome Therapeutics to develop up to three retinal disease therapies. The candidates will use Inflammasome’s intravitreal delivery technologies to get Boehringer molecules to retinal targets. Statement 

> GenSight Biologics shared more data on its Leber hereditary optic neuropathy gene therapy. The biotech plans to file for approval in Europe in the third quarter of 2020. Release 

> Tacalyx raised €7 million ($7.7 million) to generate anti-tumor associated carbohydrate antigen cancer therapies. Boehringer Ingelheim Venture Fund and Kurma Partners co-led the round. Statement 

Survey

Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

This industry survey seeks to gain insight on trial sponsors' perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first 50 qualified respondents will receive a $5 Amazon gift card.

> Kadimastem shared data from a phase 1/2a trial of its cell therapy in amyotrophic lateral sclerosis. Release 

> T3 Pharmaceuticals raised CHF 12 million (€11 million) to move its lead drug into the clinic next year. The candidate is a bacterium engineered to grow and produce therapeutic proteins in solid tumors. Statement 

> The FDA set a late February PDUFA date for Acacia Pharma’s Barhemsys. Release 

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.